Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors
Marlies H.G. Langenberg(Miltenyi Biotec (Germany)), Emile E. Voest(University Medical Center Utrecht), Carla M.L. van Herpen(Radboud University Nijmegen), Joachim Drevs(AstraZeneca (United Kingdom)), Anitra Fielding(AstraZeneca (United States)), Clemens Unger(AstraZeneca (United Kingdom)), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Walter Fiedler(Universität Hamburg), Florence Le Maulf(Boehringer Ingelheim (Germany)), Hubert E. Blum, Jan H.M. Schellens(Utrecht University), Jane Robertson(Cancer Research UK), Klaas Hoekman
Cited by 95
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k